Vanguard Group’s Palvella Therapeutics PVLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $58.7M | Buy |
560,616
+65,960
| +13% | +$5.63M | ﹤0.01% | 2078 |
|
|
2025
Q3 | $31M | Buy |
494,656
+330,847
| +202% | +$14.8M | ﹤0.01% | 2405 |
|
|
2025
Q2 | $3.69M | Buy |
163,809
+25,376
| +18% | +$596K | ﹤0.01% | 3312 |
|
|
2025
Q1 | $3.87M | Buy |
138,433
+127,091
| +1,121% | +$2.45M | ﹤0.01% | 3268 |
|
|
2024
Q4 | $136K | Hold |
11,342
| – | – | ﹤0.01% | 4142 |
|
|
2024
Q3 | $190K | Hold |
11,342
| – | – | ﹤0.01% | 4148 |
|
|
2024
Q2 | $111K | Hold |
11,342
| – | – | ﹤0.01% | 4223 |
|
|
2024
Q1 | $166K | Hold |
11,342
| – | – | ﹤0.01% | 4199 |
|
|
2023
Q4 | $165K | Sell |
11,342
-1,602
| -12% | -$29.3K | ﹤0.01% | 4244 |
|
|
2023
Q3 | $309K | Hold |
12,944
| – | – | ﹤0.01% | 4179 |
|
|
2023
Q2 | $171K | Hold |
12,944
| – | – | ﹤0.01% | 4334 |
|
|
2023
Q1 | $1.01M | Sell |
12,944
-368
| -3% | -$42.6K | ﹤0.01% | 3914 |
|
|
2022
Q4 | $1.11M | Buy |
13,312
+18
| +0.1% | +$1.45K | ﹤0.01% | 3876 |
|
|
2022
Q3 | $1.22M | Hold |
13,294
| – | – | ﹤0.01% | 3938 |
|
|
2022
Q2 | $1.99M | Hold |
13,294
| – | – | ﹤0.01% | 3811 |
|
|
2022
Q1 | $3.22M | Buy |
13,294
+24
| +0.2% | +$6.31K | ﹤0.01% | 3743 |
|
|
2021
Q4 | $4.01M | Sell |
13,270
-221
| -2% | -$70.8K | ﹤0.01% | 3731 |
|
|
2021
Q3 | $5.58M | Buy |
13,491
+28
| +0.2% | +$9.75K | ﹤0.01% | 3587 |
|
|
2021
Q2 | $4.12M | Sell |
13,463
-2,331
| -15% | -$511K | ﹤0.01% | 3690 |
|
|
2021
Q1 | $3.25M | Buy |
15,794
+1,811
| +13% | +$396K | ﹤0.01% | 3729 |
|
|
2020
Q4 | $2.8M | Buy |
13,983
+470
| +3% | +$97.7K | ﹤0.01% | 3572 |
|
|
2020
Q3 | $2.24M | Sell |
13,513
-148
| -1% | -$33.7K | ﹤0.01% | 3454 |
|
|
2020
Q2 | $3.39M | Buy |
13,661
+134
| +1% | +$31.3K | ﹤0.01% | 3261 |
|
|
2020
Q1 | $2.47M | Buy |
13,527
+658
| +5% | +$166K | ﹤0.01% | 3242 |
|
|
2019
Q4 | $3.73M | Buy |
12,869
+41
| +0.3% | +$11.4K | ﹤0.01% | 3268 |
|
|
2019
Q3 | $3.5M | Buy |
12,828
+7,483
| +140% | +$2.9M | ﹤0.01% | 3264 |
|
|
2019
Q2 | $2.01M | Sell |
5,345
-263
| -5% | -$78.5K | ﹤0.01% | 3475 |
|
|
2019
Q1 | $1.5M | Buy |
5,608
+15
| +0.3% | +$3.56K | ﹤0.01% | 3526 |
|
|
2018
Q4 | $1.19M | Buy |
5,593
+960
| +21% | +$298K | ﹤0.01% | 3515 |
|
|
2018
Q3 | $2.08M | Buy |
4,633
+554
| +14% | +$241K | ﹤0.01% | 3514 |
|
|
2018
Q2 | $1.65M | Buy |
4,079
+1,652
| +68% | +$786K | ﹤0.01% | 3557 |
|
|
2018
Q1 | $1.32M | Buy |
2,427
+1,003
| +70% | +$621K | ﹤0.01% | 3581 |
|
|
2017
Q4 | $860K | Buy |
1,424
+110
| +8% | +$51.1K | ﹤0.01% | 3641 |
|
|
2017
Q3 | $606K | Buy |
1,314
+12
| +0.9% | +$5.12K | ﹤0.01% | 3708 |
|
|
2017
Q2 | $526K | Buy |
+1,302
| New | +$380K | ﹤0.01% | 3717 |
|
Other funds holding PVLA
SCM
BI
FLSM
FLAM
SPPAM
WP
Vanguard Group's PVLA Position: Q4 2025 in Review
Vanguard Group increased its Palvella Therapeutics (PVLA) stake by 13% in Q4 2025, buying an estimated $5.63M and bringing the position to 560,616 shares worth $58.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2078.
Vanguard Group first reported a position in PVLA in Q2 2017 and has held it in 35 quarters since. 140 funds tracked by Wall St. Rank hold PVLA as of Q4 2025.
- Vanguard Group held 560,616 shares of Palvella Therapeutics worth $58.7M as of Q4 2025.
- Vanguard Group bought 65,960 Palvella Therapeutics shares in Q4 2025, an estimated $5.63M.
- Palvella Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2078 holding.
- Vanguard Group first reported a position in Palvella Therapeutics in Q2 2017 and has held it in 35 quarters since.
- 140 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.